Aging populations and clearer U.S. drug pricing boost long-term pharma outlook. Leaders like Eli Lilly and Merck lead in ...

BioMarin Pharmaceutical ( BMRN +1.56%) reported its third-quarter earnings after market close Monday, and they were good enough to push the biotech stock almost 2% higher the following day. With that ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most profitable biotech stocks to buy. Wells Fargo maintained a Buy ...

Now, it’s worth noting Stock Advisor’s total average return is 1,033% — a market-crushing outperformance compared to 193 % ...

Not just any pharmaceutical stock will do, though. They aren't all created equal. Let's discuss two leaders in the industry that look like strong buys right now: Pfizer (NYSE: PFE) and Eli Lilly (NYSE ...

Drug company Eli Lilly and NVIDIA announced a new partnership to build a supercomputer for drug research. Drug manufacturer ...

D, CIL offers pharmaceutical partners a secure, global supply of deuterated reagents – manufactured to the highest quality standards for faster, more efficient API development. TEWKSBURY, ...

Ultragenyx Pharmaceutical (RARE) shares have seen some movement lately, attracting attention from investors curious about the company’s direction. The stock has delivered a 21% gain over the past ...

The company crushed analyst profitability estimates, both for its trailing quarter and for its full-year guidance.

Besides the pharmaceutical industry, the Holy Father also criticized the influence of big tech in promoting unhealthy, ...

Fintel reports that on October 28, 2025, Morgan Stanley maintained coverage of BioMarin Pharmaceutical (NasdaqGS:BMRN) with a ...